Increased exposure w/ strong P-gp inhibitors eg, ritonavir, cyclosporine A, ketoconazole, itraconazole, erythromycin, verapamil, quinidine, tacrolimus, nelfinavir, saquinavir & amiodarone. Decreased exposure w/ strong P-gp inducers eg, rifampicin, carbamazepine, phenytoin, phenobarb, St. John's wort; high-fat meal. Increased bioavailability of BCRP substrates eg, rosuvastatin & sulfasalazine.